Clinical trialNCT07725380RecruitingPhase 1/PHASE2Interventional

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment74OsteosarcomaSarcoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Amy Armstrong, MD
Washington University School of Medicine
Principal Investigator
clinicaltrials.gov ↗
Jonathan Metts, MD
Moffitt Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Moffitt Cancer Center
Tampa, Florida, United States
Andrew Brohl, MDAnya Ibern, APRNDesiree Morales, APRNIsabel Canizares, APRNJonathan Metts, MDMauricio Silva Almeida Ribeiro, MDMihaela Druta, MD
Recruiting
Washington University in St. Louis
St Louis, Missouri, United States
Amy Armstrong, MD
Not, yet, recruiting
Montefiore Medical Center
The Bronx, New York, United States
Alice Lee, MD
Not, yet, recruiting
Nationwide Children'S Hospital
Columbus, Ohio, United States
Bhuvana Setty, MD
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DomatinostatSirolimus →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Jul 2026
Primary completion: 31 Aug 2031
Completion: 31 Aug 2031
Last update posted: 24 Jul 2026
Registered enrollment: 74
Registry id: NCT07725380

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.